Loading...
XNAS
FENC
Market cap292mUSD
Jul 09, Last price  
10.31USD
1D
0.59%
1Q
77.45%
Jan 2017
382.11%
IPO
233.66%
Name

Fennec Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:FENC chart
P/E
—
P/S
6.60
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.81%
Rev. gr., 5y
204.69%
Revenues
45m
-6.09%
00000000000000170,00001,535,00021,252,00047,538,00044,642,000
Net income
-10m
L+2,134.17%
-19,103,000-13,357,000-13,600,000-3,012,000-7,823,0004,685,000-5,163,0001,845,000-2,176,000-659,000-2,789,000-7,046,000-9,888,000-13,071,999-18,109,000-17,346,000-23,714,000-16,045,000-436,000-9,741,000
CFO
-12m
L
-13,475,000-13,303,000-10,808,000-4,688,000-1,928,000-3,226,000-2,994,000-2,210,000-1,699,000-1,862,000-2,124,000-3,641,000-7,826,000-9,060,000-15,595,000-14,222,000-18,058,000-17,143,00026,980,000-12,473,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014.
URL
https://fennecpharma.com/
IPO date
Jun 05, 2001
Employees
36
Domiciled in
US
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT